Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could common antioxidants help thalassemia patients?

NCT ID NCT07157722

Disease control Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 3 trial tests whether two antioxidant supplements, N-acetyl cysteine and alpha-lipoic acid, can improve blood vessel health and reduce oxidative stress in adults with beta thalassemia. Sixty-six participants will take one of the supplements or a placebo alongside their usual treatment for 12 weeks. The study focuses on changes in artery thickness and blood markers of inflammation and oxidative damage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
N-acetyl cysteine and alpha-lipoic acid
What this could lead to
If it works, this could point toward a simple, low-cost way to reduce heart-related complications in people with beta thalassemia.
What could go wrong
This is a small, early-stage trial with only 66 participants, and the outcomes are mainly lab markers, not direct health benefits. The supplements may not produce meaningful clinical improvements.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 66 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2025

An estimate. Start dates often move.

Expected to finish

Jan 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with beta-thalassemia who will receive conventional thalassemia management. * Both genders. * Age ≥ 18 years old. Exclusion Criteria: * Patients with familial hypercholesterolemia or history of premature atherosclerosis. * Patients with a prior history of significant cardiovascular diseases, such as coronary artery disease, myocardial infarction, or stroke. * Patients with severe renal dysfunction. * Patients with severe hepatic dysfunction. * Patients with diabetes. * Patients who will be non-compliant with the prescribed therapy. * Patients with other hemoglobinopathies. * Pregnant women. * Obese patients. * Patients who will receive antioxidant or anti-inflammatory medications. * Patients with inflammatory diseases, such as Systemic lupus erythematous, rheumatoid arthritis and inflammatory bowel disease. * Patients with oxidative stress related diseases, such as Alzheimer, Parkinson, COPD and cancer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Beta-thalassemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

beta thalassemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Beta-thalassemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Faculty of Pharmacy - Tanta University

    Tanta, 31511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.